> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Keytruda OK’d Before/After Lung Cancer Surgery
- URL: https://www.fdaweb.com/keytruda-okd-before-after-lung-cancer-surgery/
- Published: 2023-10-17T12:00:00.000Z
- Updated: 2026-09-14T14:13:34.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155578

FDA has approved Merck’s Keytruda (pembrolizumab) for use with platinum-containing chemotherapy as neoadjuvant treatment and continuing as a single-agent post-surgical adjuvant treatment for resectable non-small cell lung cancer (NSCLC). Approval was based on data from the KEYNOTE-671 trial in 797 patients with previously untreated and resectable Stage II, IIIA, or IIIB NSCLC, according to an FDA [news release](http://email.prnewswire.com/ls/click?upn=OXp-2BEvHp8OzhyU1j9bSWuwMvMWelqIco5RbfBrouY-2BR66Mz7sa-2Fm08Tm-2B9Loo0uVry5z3068RGZFxkqBrxl04r942mKo8wx-2FJpKeR6CpjG4PIxMgrmbc-2FJJCZ6MrPOg-2FuN6H6QVly87jNWO0mlmwwrTRy2tRD6gvJEVQVK9MeGtlBkxZ8jv9xiF0DS6v2uf0vm1rNLVSxMZSENiMMMXjX-2BlxByiGVeq7iQK3EE1iDJ2AmlA-2BPRxTRIONeos7kNTktRRa6oHhXAP2HgQi3VgbBn3EeL5jSF9J5DBe8tc2-2FuiMtzyt0rHwYZp1L8Px1EMwvZ7Q%5Ff0D7hj0BJ4b-2F7NuVqzPDs7FGiq8VLIwAX0sPSotqoLJejYqb1dmQHyCXe45PgGWVht5PWkwkYR5q4acUHOsZl6neuanyqtiHO0OEebkT6MJ0pdinAtjToDRi74t-2F75Jk9JD0r72ZJRxMFQhy-2BsFokgj8q2nciYfrbW4vG6mfwm3yR-2FvxtogJundFSWTjPN79GWr0-2BBv2eeUznJsKvvopRDvSMxiKvH2SNBstlG6Jc2fKkdi6s2xPyuxTDIb3rvmHsV8jZJga8jxPF3LKwWPUMw5n350bI95P84R1JLb5PDKJB307ZwYoy-2FMvsMIkfozu0mDT8u-2BJ851UD-2BLWJU2N0sYfmhhKmFzCYXaEK2UTyvI-3D&ref=fdaweb.com). “In the study, the Keytruda regimen demonstrated statistically significant improvements in event-free survival and overall survival, the study’s dual primary endpoints, versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo alone,” Merck says.